Search Results
Results found for "Chun-Chun Chang"
- Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
Kenakin reveals how scaled pharmacological metrics allow teams to interpret receptor signaling changes Drug concentrations constantly change as molecules: distribute through tissues bind and unbind receptors
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
the Danger Perhaps the most unsettling part of Catherine’s work is the disconnect between breathing changes That is why Catherine’s work matters: it shows in mechanistic detail how fentanyl and xylazine change
- β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the...
associate with the active parathyroid hormone 1 receptor (PTH1R) in different complex configurations ("hanging Moreover, we assess β-arrestin conformational changes that are induced specifically by proximal and distal Here, we show differences between conformational changes that are induced by P-R* or R* receptor states
- G protein coupling and activation of the metabotropic GABAB heterodimer
Cryo-electron microscopy studies revealed a drastic conformational change upon activation and a unique metadynamics computations to predict the mechanism by which the inactive GP induces conformational changes
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Terry Kenakin delivers a game-changing framework for teams grappling with the gap between in vitro potency His latest lecture is a guide to understanding why intracellular drug access changes everything—from
- đź“° GPCR Weekly News, November 13 to 19, 2023
cannabidiol, on the cannabinoid CB2 receptor GPCRs in Cardiology, Endocrinology, and Taste Transcriptomic changes Hartley, was at the PEGS Europe Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge
- Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery
al. highlight the importance of GPCR dimers in drug discovery referring to important conformational changes But what are the conformation changes that drive GPCR dimerization? The interaction between two receptors in a dimer involves a conformational change in the transmembrane Interestingly, the amplitude of the conformational changes due to ligand binding is limited at these
- đź“° GPCR Weekly News, February 12 to 18, 2024
If you missed the chance to register, don't worry! multifaceted role of the CXC chemokines and receptors signaling axes in ALS pathophysiology Common changes
- The Real Cost of Strategic Overload in Biotech
Which milestone truly changes the company’s valuation? Which milestone most meaningfully changes the company's valuation?
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
Assay Volume Control: Classification Through Contrast Sensitivity doesn’t merely change the size of the response—it changes the apparent identity  of the ligand.
- Gαs and Gαq/11 protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic di
characterization of biased receptors may give insights into the relationship between the conformational change protein coupling bias of mutant AVPR2s may broaden our understanding of the relationship between the changed
- đź“° GPCR Weekly News, March 20 to 26, 2023
Structural and Molecular Insights into GPCR Function Physiological changes in bilayer thickness induced Ultrafast structural changes direct the first molecular events of vision. Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting
- Enhanced membrane binding of oncogenic G protein αqQ209L confers resistance to inhibitor YM-254890
Additionally, pull-down experiments demonstrated that YM promotes similar conformational changes in both Together, these results indicate that changes in membrane binding impact the ability of YM to inhibit
- Dynamic recognition of naloxone, morphine and endomorphin1 in the same pocket of µ-opioid receptors
severe pain by activating the ÎĽ-opioid receptor (MOR), whereas naloxone, with only slight structural changes The endogenous peptide ligand endomorphin-1 (EM-1) underwent almost no significant conformational changes
- Accelerating GPCR Drug Discovery
Traditional roles rarely gave me the freedom to implement these changes at the scale needed.
- Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization
“You’re not changing the spectrum,” Trinquet explains. “You’re changing how bright it is—and how long it glows.”
- Beyond HEK293 — Terry Hébert on iPSC-Derived GPCR Models, Live April 16,
This week's session examines what changes when you close that gap. Terry Hébert joins the Dr.
- From DNA day to GPCR genomics
Thanks to recent scientific advances, we now have a better understanding of the structural changes that Additionally, there have been recent discoveries of the conformational changes that occur during G-protein
- The NPXXY Motif Regulates β-Arrestin Recruitment by the CB1 Cannabinoid Receptor
transmembrane helix 7 (TMH7) and the highly conserved NPXXY motif can be subject to different conformational changes
- Synaptic integration of subquantal neurotransmission by co-localized G protein coupled receptors in
We tested effects of changes in vesicle numbers undergoing fusion at single synapses, relative placement Experimental effects of Pr changes, consistent with GABAB receptor effects, were straightforwardly represented by changes in numbers of synapses. GABAB receptors alter Pr leaving synaptic properties unchanged, while 5-HT1B receptors fundamentally change
- When the Assay Says Nothing, Look Again: Kinetic Detection of Multi-Target GPCR Activity
Hybrid ligand design: how two pharmacophores are encoded into one scaffold, and why a uniform PK profile changes
- β2-Adrenergic Receptor Expression and Intracellular Signaling in B Cells Are Highly Dynamic during..
-ADR agonist terbutaline by flow cytometry. β2-ADR-expressing B cells increase during CIA without a change The change of β2-ADR expression and signaling during sustained inflammation might be an integral part
- Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and...
August 2022 Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes
- How Fast Does a Drug Work?
Competitive conditions —such as the presence of endogenous ligands— change kinetic behavior , and ignoring
- Integrated GPCR Drug Discovery: A Structured Framework for Modern Programs
Why this matters: Membrane context changes signaling outcomes.
- đź“° GPCR Weekly News, September 4 to 10, 2023
Magazine's for Pioneering AI-Driven Drug Discovery Domain Therapeutics CEO Pascal Neuville to Discuss Game-Changing Drug Targets: Allosteric Function and Biased Signaling" at the DOT October 3, 2023 | FREE Seminar: Changing
- Early Safety Assays: Identifying Showstoppers in GPCR Drug Discovery Pipelines Early
/no-go choices Strategic insights into early identification and mitigation of drug liabilities Game-Changing
- Radioligands vs. Fluorescent Ligands: Binding Assays
with a higher specific activity, but a shorter half-life (60 days), which complicates storage, besides changing
- ShouTi Pharma has a brand new website
experienced, innovative, global team on a bold mission to improve health by creating and developing life-changing
- Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
A much smaller conformational change of helix VI upon activation than previously solved class A GPCR-Gi













